

Application No. 10/016,371

Attorney Ref. No. P02194US0

**b.) Amendments to the Claims:**

The following is a list of claims currently pending in the application, along with status modifiers.

1. (Previously presented) A method of increasing a high-density lipoprotein level in plasma in a postmenopausal woman comprising the steps of administering a pharmaceutical formulation comprising calcium citrate at a therapeutically effective dose and measuring the high-density lipoprotein level in said woman, wherein if the high-density lipoprotein level in plasma is increased, the administering the pharmaceutical formulation comprising calcium citrate is continued for at least about two months.
2. (Original) The method of claim 1, wherein the high-density lipoprotein level in plasma is increased at least about 5% in said woman.
3. (Original) The method of claim 1, wherein the high-density lipoprotein level in plasma is increased at least about 7.7% in said woman.
4. (Previously presented) The method of claim 1, wherein the therapeutically effective dose of calcium citrate is equivalent to at least about 1 g elemental calcium per day.
5. (Canceled)
6. (Previously presented) The method of claim 1, wherein the pharmaceutical formulation comprises calcium citrate in an amount equivalent to at least from about 10 mg to about 1 g elemental calcium per day.
7. (Canceled)
8. (Original) The method of claim 1, wherein said administering is for at least about 6 months.

Application No. 10/016,371

Attorney Ref. No. P02194US0

9. (Original) The method of claim 1, wherein said administering is for at least about 12 months.
10. (Canceled)
11. (Previously presented) A method of increasing a high-density lipoprotein level in plasma by about 7.7% in a postmenopausal woman comprising the steps of administering calcium citrate in an amount equivalent to about 1 g elemental calcium per day, and measuring the high-density lipoprotein level in said woman, wherein if the high-density lipoprotein level in plasma is increased, the administering the pharmaceutical formulation comprising calcium citrate is continued for at least about two months.
12. (Previously presented) A method of increasing a ratio of high-density lipoprotein to low-density lipoprotein in a postmenopausal woman comprising the steps of administering a pharmaceutical formulation comprising calcium citrate at a therapeutically effective dose, and measuring the ratio of high-density lipoprotein to low-density lipoprotein in said woman, wherein if the ratio of high-density lipoprotein to low-density lipoprotein is increased, the administering the pharmaceutical formulation comprising calcium citrate is continued for at least about two months.
13. (Previously presented) The method of claim 12, wherein said ratio is increased by at least about 17% in said woman.
14. (Previously presented) The method of claim 12, wherein said calcium citrate is in a quantity sufficient to provide at least about 1 g elemental calcium per day.
15. (Previously presented) The method of claim 12, wherein said administering is for at least about 6 months.
16. -21 (Canceled)

Application No. 10/016,371

Attorney Ref. No. P02194US0

22. (Previously presented) The method of claim 1, wherein the postmenopausal women are at least 10 years postmenopause.